CDKI-73

Research use only, not for human use.

CDKI-73 is a potent CDK9 inhibitor with Ki of 4 nM, shows cytotoxicity against a broad CLL samples with mean LD50 of 80 nM.

CDKI-73 is a potent CDK9 inhibitor with Ki of 4 nM, shows cytotoxicity against a broad CLL samples with mean LD50 of 80 nM; induces caspase-dependent apoptosis that was preceded by dephosphorylation of CDK9 and serine 2 of RNA polymerase II; CDKI-73 is more potent than the pan-CDK inhibitor Flavopiridol and shows >200-fold selectivity against primary leukemia cells when compared with normal CD34+ cells; shows cytotoxic synergy with the nucleoside analog fludarabine in in poor prognostic sub-groups of leukemia patients, which is associated with CDKI-73-mediated transcriptional inhibition of MCL1 and XIAP.

CDKI73

Angiogenesis

CDK

CDK

Cancer

——

1421693-22-2

394.45

C15H15FN6O2S2

>98% (HPLC)

10 mM in DMSO

O=S(C1=CC=CC(NC2=NC=C(F)C(C3=C(C)N=C(NC)S3)=N2)=C1)(N)=O

Benzenesulfonamide, 3-[[5-fluoro-4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]-

(-20℃)

With Ice Pack

≥ 2 years